Maxim analyst Matthew Galinko lowered the firm’s price target on Semler Scientific (SMLR) to $80 from $95 and keeps a Buy rating on the shares. The firm is cutting its estimates for revenue in 2025-27 due to the management’s guidance and its own estimates, the analyst tells investors in a research note. Maxim also cites Semler having entered into a settlement agreement with the Civil Fraud Section of the Department of Justice, the Department of Health and Human Services, and certain relators to settle all potential claims related to alleged civil violations of the False Claims Act, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMLR:
- Semler Scientific Faces Lawsuit Amid Revenue Concerns
- Semler Faces Legal Storm Over DOJ Investigation
- Semler Scientific’s Stockholder Meeting Approves Key Proposals
- Crypto Currents: Trump signs executive order to allow crypto in 401(k) plans
- Semler Scientific: Strategic Bitcoin Accumulation and Medical Expansion Drive Buy Rating